Rezolute to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rezolute (NASDAQ: RZLT), a late-stage rare disease company specializing in treatments for hypoglycemia caused by hyperinsulinism, has announced its participation in four upcoming investor conferences in May and June 2025. The company's management will attend:

• The Citizens JMP Life Sciences Conference (May 7-8)
• H.C. Wainwright BioConnect Investor Conference (May 20)
• Craig-Hallum Institutional Investor Conference (May 28)
• Jefferies Global Healthcare Conference (June 3-5)

Management will be available for one-on-one meetings with investors during these conferences. Interested investors should contact their respective conference representatives to schedule meetings.

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

Event: The Citizens JMP Life Sciences Conference
Date: May 7-8, 2025

Event: H.C. Wainwright BioConnect Investor Conference
Date: May 20, 2025

Event: Craig-Hallum Institutional Investor Conference
Date: May 28, 2025

Event: Jefferies Global Healthcare Conference
Date: June 3-5, 2025

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their JMP, H.C. Wainwright, Craig-Hallum, and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.

Contact:

Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Media
Sarah Lima
Sarah@GalvinPR.com
(774) 766-0200

FAQ

What investor conferences will Rezolute (RZLT) attend in May-June 2025?

Rezolute will attend four conferences: The Citizens JMP Life Sciences Conference (May 7-8), H.C. Wainwright BioConnect Investor Conference (May 20), Craig-Hallum Institutional Investor Conference (May 28), and Jefferies Global Healthcare Conference (June 3-5).

What is Rezolute's (RZLT) main business focus?

Rezolute is a late-stage rare disease company focused on developing treatments for hypoglycemia caused by hyperinsulinism.

How can investors meet with Rezolute's management at these conferences?

Investors interested in one-on-one meetings should contact their JMP, H.C. Wainwright, Craig-Hallum, or Jefferies representatives to schedule meetings.

What stock exchange is Rezolute (RZLT) listed on?

Rezolute (RZLT) is listed on the Nasdaq stock exchange.